James Kalabus, PhD (he/him/his)

Sr. Director, Translational & Clinical Pharmacology
Inhibrx Biosciences, Inc
La Jolla, California, United States

Clinical pharmacologist supporting the development of drug candidates by characterizing their exposure profile and resultant downstream pharamacodynamic effects. Experience in informing first-in-human dose selection through recommended Phase 2 dosing and regulatory submissions. Specializing in analyzing pharmacokinetic data through non-compartmental analysis as well as pharmacometric tools for population PK modeling, covariate analyses, simulations, exposure/response relationship characterization and more.

Presentation(s):

• Paper 31 - THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY

  Friday, November 14, 2025
  8:30 AM - 10:00 AM EST

  Disclosure information not submitted.